NEU-627
/ Neuron23
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
February 04, 2026
Central TYK2Inhibition Impairs Interferon Responsive Glial Activation in EAE: an snRNA-seq Study
(ACTRIMS Forum 2026)
- "cTYK2 inhibition extinguishes the smoldering neuroinflammatory signal emanating from activated glial cells thereby halting infiltration and maturation of peripheral immune cells. cTYK2i attacks both inside-out and outside-in pathogenic mechanisms driving MS. cTYK2i is uniquely positioned to address the pathologic mechanisms driving progressive MS."
IO biomarker • CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • CD40 • CXCL13 • CXCL9 • CXCR5 • TYK2
January 16, 2026
A Study to Assess NEU-627 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=74 | Completed | Sponsor: Neuron23 Inc. | Recruiting ➔ Completed
Trial completion
June 13, 2025
A Study to Assess NEU-627 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=96 | Recruiting | Sponsor: Neuron23 Inc. | Not yet recruiting ➔ Recruiting
Enrollment open
March 24, 2025
Central TYK2 inhibition identifies TYK2 as a key neuroimmune modulator.
(PubMed, Proc Natl Acad Sci U S A)
- "We deployed brain-penetrant TYK2 inhibitors (cTYK2i) alongside the peripherally restricted TYK2 inhibitor (pTYK2i; BMS-986165) to untangle the contributions of central TYK2 inhibition in diverse models of neuroinflammation. Finally, we demonstrate TYK2 inhibition has a robust impact on a unique subset of activated astrocytes termed Interferon-Responsive-Reactive-Astrocytes (IRRA). The data presented herein identify a key role for CNS TYK2 signaling in regulating neuroinflammation and solidify TYK2 as a potential therapeutic target for MS."
Journal • CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • TYK2
July 08, 2024
Central TYK2 Inhibition Identifies TYK2 as a Key Neuroimmune Modulator
(ECTRIMS 2024)
- " We deployed our brain penetrant TYK2 inhibitors (cTYK2i) alongside the systemic TYK2 inhibitor (sTYK2i; BMS-986165) in diverse forms of EAE models to untangle the contributions of central TYK2 inhibition on EAE pathophysiology using selective pharmacology. The data presented herein suggests a key role for CNS TYK2 signaling in regulating neuroinflammation and solidifies TYK2 as a potential therapeutic target for MS."
CNS Disorders • Immunology • Inflammation • Multiple Sclerosis • TYK2
1 to 5
Of
5
Go to page
1